Sam Chun Dang Pharm. Co. Ltd Net Assets
Sam Chun Dang Pharm. Co. Ltd net assets. Based on the latest financial reports, Sam Chun Dang Pharm. Co. Ltd (000250) has net assets worth ₩400.79 Billion KRW (≈ $271.61 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩575.39 Billion ≈ $389.93 Million USD) and total liabilities (₩174.61 Billion ≈ $118.33 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore net asset growth rate of Sam Chun Dang Pharm. Co. Ltd to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩400.79 Billion |
| % of Total Assets | 69.65% |
| Annual Growth Rate | 11.67% |
| 5-Year Change | 108.85% |
| 10-Year Change | 190.49% |
| Growth Volatility | 23.0 |
Net Assets of Sam Chun Dang Pharm. Co. Ltd (2012–2025)
Net assets of Sam Chun Dang Pharm. Co. Ltd from 2012 to 2025. This chart illustrates how Sam Chun Dang Pharm. Co. Ltd's net assets have evolved over time, based on quarterly financial data. See 000250 net asset quality index to measure how much of total assets are equity-financed.
Annual Net Assets for Sam Chun Dang Pharm. Co. Ltd (2012–2025)
The table below shows the annual net assets of Sam Chun Dang Pharm. Co. Ltd from 2012 to 2025. For live market cap and overall valuation, see Sam Chun Dang Pharm. Co. Ltd (000250) market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩363.59 Billion ≈ $246.40 Million |
+36.64% |
| 2024-12-31 | ₩266.11 Billion ≈ $180.34 Million |
-10.84% |
| 2023-12-31 | ₩298.46 Billion ≈ $202.26 Million |
+71.78% |
| 2022-12-31 | ₩173.74 Billion ≈ $117.74 Million |
-0.20% |
| 2021-12-31 | ₩174.09 Billion ≈ $117.98 Million |
-6.71% |
| 2020-12-31 | ₩186.63 Billion ≈ $126.47 Million |
+18.21% |
| 2019-12-31 | ₩157.87 Billion ≈ $106.99 Million |
+6.30% |
| 2018-12-31 | ₩148.52 Billion ≈ $100.65 Million |
+5.08% |
| 2017-12-31 | ₩141.34 Billion ≈ $95.78 Million |
+12.92% |
| 2016-12-31 | ₩125.17 Billion ≈ $84.82 Million |
+9.49% |
| 2015-12-31 | ₩114.32 Billion ≈ $77.47 Million |
-18.16% |
| 2014-12-31 | ₩139.68 Billion ≈ $94.66 Million |
+17.15% |
| 2013-12-31 | ₩119.23 Billion ≈ $80.80 Million |
+37.63% |
| 2012-12-31 | ₩86.63 Billion ≈ $58.71 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Sam Chun Dang Pharm. Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 67.2% over the analyzed period, indicating profitable operations and earnings retention.
Sam Chun Dang Pharm. Co. Ltd Net Assets Breakdown (December 2025)
Sam Chun Dang Pharm. Co. Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩95.97 Billion | 34.77% |
| Other Components | ₩180.05 Billion | 65.23% |
| Total Equity | ₩276.02 Billion | 100.00% |
Sam Chun Dang Pharm. Co. Ltd Competitors by Market Cap
The table below lists competitors of Sam Chun Dang Pharm. Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Beijing Venustech Inc
SHE:002439
|
$2.49 Billion |
|
Sai MicroElectronics Inc
SHE:300456
|
$2.49 Billion |
|
IIFL Finance Limited
NSE:IIFL
|
$2.49 Billion |
|
Fujian Newland Computer Co Ltd
SHE:000997
|
$2.49 Billion |
|
CompoSecure, Inc.
NASDAQ:CMPO
|
$2.49 Billion |
|
Qinhuangdao Port Co Ltd
SHG:601326
|
$2.49 Billion |
|
Interparfums SA
PA:ITP
|
$2.48 Billion |
|
Sociedad Punta del Cobre S.A
SN:PUCOBRE
|
$2.48 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Sam Chun Dang Pharm. Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 266,105,335,240 to 276,019,546,060, a change of 9,914,210,820 (3.7%).
- Net income of 5,261,822,740 contributed positively to equity growth.
- Dividend payments of 4,651,494,400 reduced retained earnings.
- New share issuances of 90,281,150 increased equity.
- Other factors increased equity by 9,213,601,330.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩5.26 Billion | +1.91% |
| Dividends Paid | ₩4.65 Billion | -1.69% |
| Share Issuances | ₩90.28 Million | +0.03% |
| Other Changes | ₩9.21 Billion | +3.34% |
| Total Change | ₩- | 3.73% |
Book Value vs Market Value Analysis
This analysis compares Sam Chun Dang Pharm. Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 14.54x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 29.17x to 14.54x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩5876.20 | ₩171400.00 | x |
| 2017-12-31 | ₩6602.83 | ₩171400.00 | x |
| 2018-12-31 | ₩6938.23 | ₩171400.00 | x |
| 2019-12-31 | ₩7375.20 | ₩171400.00 | x |
| 2020-12-31 | ₩8456.84 | ₩171400.00 | x |
| 2021-12-31 | ₩7889.00 | ₩171400.00 | x |
| 2022-12-31 | ₩7872.97 | ₩171400.00 | x |
| 2023-12-31 | ₩9718.51 | ₩171400.00 | x |
| 2024-12-31 | ₩11441.71 | ₩171400.00 | x |
| 2025-12-31 | ₩11791.94 | ₩171400.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Sam Chun Dang Pharm. Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.91%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.27%
- • Asset Turnover: 0.41x
- • Equity Multiplier: 2.03x
- Recent ROE (1.91%) is below the historical average (3.37%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | 1.63% | 1.75% | 0.63x | 1.49x | ₩-6.87 Billion |
| 2013 | 9.37% | 8.34% | 0.67x | 1.67x | ₩-588.58 Million |
| 2014 | 11.24% | 9.96% | 0.69x | 1.64x | ₩1.30 Billion |
| 2015 | 10.17% | 8.81% | 0.72x | 1.61x | ₩196.52 Million |
| 2016 | 6.96% | 5.91% | 0.72x | 1.64x | ₩-3.80 Billion |
| 2017 | 8.85% | 7.79% | 0.70x | 1.63x | ₩-1.62 Billion |
| 2018 | 5.89% | 5.47% | 0.61x | 1.76x | ₩-6.10 Billion |
| 2019 | 6.62% | 5.60% | 0.64x | 1.84x | ₩-5.34 Billion |
| 2020 | -0.52% | -0.58% | 0.53x | 1.70x | ₩-19.63 Billion |
| 2021 | -9.51% | -9.90% | 0.48x | 1.99x | ₩-33.96 Billion |
| 2022 | 3.36% | 3.29% | 0.48x | 2.15x | ₩-11.54 Billion |
| 2023 | -4.71% | -5.39% | 0.47x | 1.85x | ₩-32.43 Billion |
| 2024 | -4.10% | -5.18% | 0.41x | 1.95x | ₩-37.53 Billion |
| 2025 | 1.91% | 2.27% | 0.41x | 2.03x | ₩-22.34 Billion |
Industry Comparison
This section compares Sam Chun Dang Pharm. Co. Ltd's net assets metrics with peer companies in the Pharmaceuticals industry.
Industry Context
- Industry: Pharmaceuticals
- Average net assets among peers: $82,693,436,892
- Average return on equity (ROE) among peers: 14.89%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Sam Chun Dang Pharm. Co. Ltd (000250) | ₩400.79 Billion | 1.63% | 0.44x | $2.49 Billion |
| DongKoo Bio & Pharma Co. Ltd. (006620) | $2.55 Billion | 158.01% | 22.83x | $21.80 Million |
| NatureCell Co.Ltd (007390) | $13.75 Billion | 13.78% | 0.78x | $793.12 Million |
| Sam-A Pharm. Co. Ltd (009300) | $200.47 Billion | 10.66% | 0.15x | $56.13 Million |
| Kyung Dong Pharmaceutical Co. Ltd (011040) | $259.82 Billion | 4.88% | 0.12x | $78.42 Million |
| WooGene B&G Co. Ltd (018620) | $27.27 Billion | -46.89% | 2.12x | $46.98 Million |
| Oscotec Inc (039200) | $21.78 Billion | -9.28% | 0.67x | $674.16 Million |
| EstechPharma Co. Ltd (041910) | $115.63 Billion | 3.31% | 0.05x | $42.90 Million |
| Komipharm International Co. Ltd (041960) | $60.02 Billion | -6.63% | 0.98x | $343.99 Million |
| Eagle Veterinary Technology Co.Ltd (044960) | $42.95 Billion | 6.15% | 0.28x | $25.96 Million |
About Sam Chun Dang Pharm. Co. Ltd
Sam Chun Dang Pharm. Co., Ltd manufactures, distributes, imports, and exports pharmaceuticals in South Korea. It provides ophthalmology, cardiovascular, endocrinology, antibacterial, anti-fungal, antiviral, respiratory, anti-inflammatory, antihistamine, and musculoskeletal products, as well as vitamins and gastro intestine products. The company was founded in 1943 and is headquartered in Seoul, S… Read more